Pharmaceutical composition

Details Pharmaceutical composition Pharmaceutical composition

2011-05-03

2011-05-03

Sajjadi, Fereydoun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

07935690

ABSTRACT:
A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

REFERENCES:
patent: 3989815 (1976-11-01), Rajadhyaksha
patent: 3989816 (1976-11-01), Rajadhyaksha
patent: 3991203 (1976-11-01), Rajadhyaksha
patent: 4122170 (1978-10-01), Rajadhyaksha
patent: 4316893 (1982-02-01), Rajadhyaksha
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4415563 (1983-11-01), Rajadhyaksha
patent: 4423040 (1983-12-01), Rajadhyaksha
patent: 4424210 (1984-01-01), Rajadhyaksha
patent: 4444762 (1984-04-01), Rajadhyaksha
patent: 4992422 (1991-02-01), Minaskanian et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5676968 (1997-10-01), Lipp et al.
patent: 6190691 (2001-02-01), Mak
patent: 6200602 (2001-03-01), Watts et al.
patent: 6319913 (2001-11-01), Mak et al.
patent: 6385475 (2002-05-01), Cinquin et al.
patent: 6503894 (2003-01-01), Dudley et al.
patent: 6506572 (2003-01-01), Biedermann et al.
patent: 6723339 (2004-04-01), Meinzer et al.
patent: 7037499 (2006-05-01), Glenn et al.
patent: 7320968 (2008-01-01), Gyurik
patent: 7608605 (2009-10-01), Gyurik
patent: 7608606 (2009-10-01), Gyurik
patent: 7608607 (2009-10-01), Gyurik
patent: 7608608 (2009-10-01), Gyurik
patent: 7608609 (2009-10-01), Gyurik
patent: 7608610 (2009-10-01), Gyurik
patent: 2002/0006951 (2002-01-01), Hageman et al.
patent: WO 02089849 (2002-11-01), None
MerckSource, Dorland's Medical Dictionary—Analgoue, 2007, printed Feb. 17, 2009 from http://www.mercksource.com/pp/us/cns/cns—hl—dorlands—split.jsp?pg=/ppdocs/us/common/dorlands/dorland/one/000004228.htm, 2 pages.
Kenny et al. “Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and Hematocrit in men over age 70 with low testosterone levels”, Endocrine Research, 2000, vol. 26, No. 2, pp. 153-168.
Potts RO, Guy RH. “Predicting skin permeability,” Pharm Res. May 1992; 9(5):663-9.
Scheuplein RJ et al., “Percutaneous absorption of steroids,” J Invest Dermatol. Jan. 1969;52(1):63-70.
Feldmann RJ, Maibach HI. “Percutaneous penetration of steroids in man,” J Invest Dermatol. Jan. 1969;52(1):89-94.
Frum Y, et al. “Towards a correlation between drug properties and in vitro transdermal flux variability,” Int J Pharm. May 4, 2007;336(1):140-7.
Magnusson BM, et al., “Molecular size as the main determinant of solute maximum flux across the skin,”J Invest Dermatol. Apr. 2004;122(4):993-9.

Affiliated with

Also associated with

Rating

Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2662091